FIELD: pharmaceutical industry, medicine.
SUBSTANCE: the invention relates to a substituted quinoxaline of general formula 1, where R1 and R2 are optionally the same hydrogen or halogen atoms, R3 is a hydrogen atom, provided that R1, R2 and R3 are not simultaneously hydrogen, or both R1 and R2 are not 6 ,7-dichloro, or if R1 is hydrogen, then R2 is not 7-chloro. The invention also relates to a pharmaceutical composition having the property of an inhibitor of RNA-dependent RNA polymerase (RdRp) of RNA viruses, based on the specified compound of formula 1.
EFFECT: new compounds and pharmaceutical compositions based on them have been obtained, which can be used in medicine as agents that inhibit RNA-dependent RNA polymerase (RdRp) RNA viruses, where the virus is SARS-CoV-2 coronavirus and influenza virus.
5 cl, 1 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
| SUBSTITUTED 3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCTION AND USE THEREOF | 2019 |
|
RU2720305C1 |
| PRODRUG OF POLYMERASE NS5B HCV INHIBITOR, METHOD FOR ITS PREPARATION AND APPLICATION | 2017 |
|
RU2644156C1 |
| ANTIVIRAL COMPOSITION AND METHOD OF ITS APPLICATION | 2017 |
|
RU2650610C1 |
| ANELLATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-7-CARBOXAMIDES - INTEGRASE INHIBITORS, METHODS FOR PREPARING AND USING THEREOF | 2019 |
|
RU2717101C1 |
| ANTICORONAVIRUS THERAPEUTIC AGENT - SUBSTITUTED 7-HYDROXY-3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE FOR THE PREVENTION AND TREATMENT OF COVID-19 | 2020 |
|
RU2745985C1 |
| HEPATITIS B (HBV) INHIBITOR | 2017 |
|
RU2666727C1 |
| SUBSTITUTED (2R,3R,5R)-3-HYDROXY-(5-PYRIMIDIN-1-YL)TETRAHYDROFURAN-2-YLMETHYL ARYL PHOSPHORAMIDATES | 2013 |
|
RU2553996C1 |
| ANTI-CORONAVIRUS AGENT FOR COVID-19 COMBINATION THERAPY (SARS-COV-2) | 2020 |
|
RU2742116C1 |
